Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Welzel TM, et al. Among authors: fried mw. Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13. Gut. 2017. PMID: 27418632 Free PMC article.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Fried MW, et al. N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047. N Engl J Med. 2002. PMID: 12324553 Free article. Clinical Trial.
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Zeuzem S, et al. Among authors: fried mw. J Hepatol. 2003 Jul;39(1):106-11. doi: 10.1016/s0168-8278(03)00187-9. J Hepatol. 2003. PMID: 12821051 Clinical Trial.
Management of newly diagnosed hepatitis C virus infection.
Russo MW, Zacks SL, Fried MW. Russo MW, et al. Among authors: fried mw. Cleve Clin J Med. 2003 Sep;70 Suppl 4:S14-20. doi: 10.3949/ccjm.70.suppl_4.s14. Cleve Clin J Med. 2003. PMID: 14558641 Free article. Review.
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, Shiffman ML, Minuk G, Reddy KR, Reindollar RW, Lin A, Brunda MJ; PEGASYS International Study Group. Pockros PJ, et al. Among authors: fried mw. Am J Gastroenterol. 2004 Jul;99(7):1298-305. doi: 10.1111/j.1572-0241.2004.30306.x. Am J Gastroenterol. 2004. PMID: 15233669 Clinical Trial.
Optimizing treatment regimens in hepatitis C.
Darling JM, Fried MW. Darling JM, et al. Among authors: fried mw. Clin Liver Dis. 2006 Nov;10(4):835-50. doi: 10.1016/j.cld.2006.08.024. Clin Liver Dis. 2006. PMID: 17164120 Review.
237 results